Clinical study on Shenmai Injection combined with levosimendan in treatment of dilated cardiomyopathy refractory heart failure
Author(s): CHEN Ke-rang, ZHU Jiang, HUANG Ming-Yong
Pages: 772-775
Year: 2016 Issue: 6
Journal: World Phytomedicines
Keyword: Shenmai Injection; Levosimendan Injection; dilated cardiomyopathy refractory heart failure;
Abstract: Objective To observe the clinical effect of Shenmai Injection combined with levosimendan in treatment of dilated cardiomyopathy refractory heart failure. Methods Patients (80 cases) with dilated cardiomyopathy refractory heart failure in Hospital of Integrated Chinese and Western Medicine of Changjiang Li Autonomous County from July 2013 to April 2015 were randomly divided into the control and treatment groups, and each group had 40 cases. Patients in the control group were given Levosimendan Injection, initial loading dose was 12 μg/kg, time of intravenous injection was more than 10 min, then 0.075 μg/(kg·min) was continually pumping for 24 h by micro pump. Patients in the treatment group were iv administered with Shenmai Injection on the basis of the control group, 60 mL added into 5%glucose solution 150 mL, once daily, and treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and 6 MWT, BNP, and cardiac function in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 72.50%and 92.50%, respectively, and there was difference between two groups (P<0.05). After treatment, 6 MWT distances in two groups were obviously increased, but BNP levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, CO, CI, and EF in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Shenmai Injection combined with levosimendan has clinical curative effect in treatment of dilated cardiomyopathy refractory heart failure, and can significantly improve cardiac function, enhance athletic ability, which has a certain clinical application value.
Pages: 772-775
Year: 2016 Issue: 6
Journal: World Phytomedicines
Keyword: Shenmai Injection; Levosimendan Injection; dilated cardiomyopathy refractory heart failure;
Abstract: Objective To observe the clinical effect of Shenmai Injection combined with levosimendan in treatment of dilated cardiomyopathy refractory heart failure. Methods Patients (80 cases) with dilated cardiomyopathy refractory heart failure in Hospital of Integrated Chinese and Western Medicine of Changjiang Li Autonomous County from July 2013 to April 2015 were randomly divided into the control and treatment groups, and each group had 40 cases. Patients in the control group were given Levosimendan Injection, initial loading dose was 12 μg/kg, time of intravenous injection was more than 10 min, then 0.075 μg/(kg·min) was continually pumping for 24 h by micro pump. Patients in the treatment group were iv administered with Shenmai Injection on the basis of the control group, 60 mL added into 5%glucose solution 150 mL, once daily, and treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and 6 MWT, BNP, and cardiac function in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 72.50%and 92.50%, respectively, and there was difference between two groups (P<0.05). After treatment, 6 MWT distances in two groups were obviously increased, but BNP levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, CO, CI, and EF in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Shenmai Injection combined with levosimendan has clinical curative effect in treatment of dilated cardiomyopathy refractory heart failure, and can significantly improve cardiac function, enhance athletic ability, which has a certain clinical application value.
Related Articles